IN2015DN01135A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01135A
IN2015DN01135A IN1135DEN2015A IN2015DN01135A IN 2015DN01135 A IN2015DN01135 A IN 2015DN01135A IN 1135DEN2015 A IN1135DEN2015 A IN 1135DEN2015A IN 2015DN01135 A IN2015DN01135 A IN 2015DN01135A
Authority
IN
India
Prior art keywords
salt forms
maleate salt
maleate
pyridinylmethoxy
butenamide
Prior art date
Application number
Other languages
English (en)
Inventor
K Cheal Gloria
Chew Warren
F Hadfield Anthony
Sherry Ku Mannching
Lu Qinghong
Mirmehrabi Mahmoud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN01135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of IN2015DN01135A publication Critical patent/IN2015DN01135A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IN1135DEN2015 2007-10-17 2008-10-16 IN2015DN01135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12479607P 2007-10-17 2007-10-17
PCT/US2008/080130 WO2009052264A2 (en) 2007-10-17 2008-10-16 Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Publications (1)

Publication Number Publication Date
IN2015DN01135A true IN2015DN01135A (es) 2015-07-10

Family

ID=40347915

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1135DEN2015 IN2015DN01135A (es) 2007-10-17 2008-10-16

Country Status (20)

Country Link
US (7) US8022216B2 (es)
EP (6) EP2537843B1 (es)
JP (11) JP2011500712A (es)
KR (5) KR20130025862A (es)
CN (7) CN110452221A (es)
AR (2) AR068932A1 (es)
AU (1) AU2008312474B2 (es)
BR (2) BRPI0818464B8 (es)
CA (2) CA2928071C (es)
CL (1) CL2008003088A1 (es)
ES (3) ES2602123T3 (es)
IL (3) IL308687A (es)
IN (1) IN2015DN01135A (es)
MX (5) MX387683B (es)
NZ (3) NZ616136A (es)
PA (1) PA8800701A1 (es)
RU (2) RU2463300C2 (es)
SG (2) SG185312A1 (es)
TW (1) TW200934761A (es)
WO (1) WO2009052264A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US8586598B2 (en) * 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CA2783743C (en) 2009-12-11 2022-10-04 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
EP2716633B1 (en) * 2011-05-26 2017-05-17 Xuanzhu Pharma Co., Ltd. Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN104513200B (zh) * 2013-09-26 2017-05-03 江苏苏中药业集团股份有限公司 取代丁烯酰胺的马来酸盐及其晶型
EP3229861B1 (en) * 2014-12-12 2019-01-30 Sanofi Medical apparatus package
US20170340806A1 (en) * 2014-12-12 2017-11-30 Sanofi Medical apparatus package
CN105367552A (zh) 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法
WO2016210345A1 (en) 2015-06-25 2016-12-29 The California Institute For Biomedical Research Composition and methods for inhibiting mammalian sterile 20-like kinase 1
CN105949176B (zh) * 2016-06-24 2018-10-26 浙江海正药业股份有限公司 一种来那替尼的纯化方法
US20200308141A1 (en) 2016-06-27 2020-10-01 Pliva Hrvatska D.O.O. Solid state forms of neratinib and salts thereof
CN107721986A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721985A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
WO2018028673A1 (zh) * 2016-08-12 2018-02-15 山东轩竹医药科技有限公司 喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型
CN107721987A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
WO2018134843A1 (en) * 2017-01-23 2018-07-26 Msn Laboratories Private Limited, R&D Center Polymorphic forms of (e)-n-{4-[3-chloro-4-((pyridin-2-yl methoxy)anilino]-3-cyano-7- ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, its maleate salt and process for preparation thereof
WO2018189695A1 (en) * 2017-04-11 2018-10-18 Lupin Limited Neratinib crystalline forms and process for preparation thereof
WO2019015394A1 (zh) * 2017-07-17 2019-01-24 苏州科睿思制药有限公司 一种来那替尼单马来酸盐的晶型及其制备方法和用途
CN111344280B (zh) * 2017-11-20 2022-08-12 苏州韬略生物科技股份有限公司 (e)-n-(3-氰基-7-乙氧基-4-((4-苯氧基苯基)氨基)喹啉-6-基)-4-(二甲基氨基) 丁-2-烯酰胺马来酸盐及晶型
CN107698563B (zh) * 2017-11-23 2020-10-30 江苏创诺制药有限公司 制备马来酸来那替尼晶型的方法
CN108299394A (zh) * 2018-02-28 2018-07-20 江苏创诺制药有限公司 来那替尼二马来酸盐晶型及其制备方法
CN110357855A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼盐酸盐晶型及其制备方法
CN109053683A (zh) * 2018-07-27 2018-12-21 苏州晶云药物科技股份有限公司 来那替尼马来酸盐晶型c的制备方法以及来那替尼马来酸盐晶型c
CN109053702A (zh) * 2018-08-13 2018-12-21 扬子江药业集团有限公司 一种阿法替尼类似物及其制备方法和用途
CN109503479A (zh) * 2018-12-03 2019-03-22 四川自豪时代药业有限公司 一种磷酸萘酚喹工艺杂质及其合成方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN114380745A (zh) * 2020-10-19 2022-04-22 江苏苏中药业集团股份有限公司 一种取代丁烯酰胺颗粒混合物及晶型ii制备方法与应用
CN116723845A (zh) * 2020-11-02 2023-09-08 特雷西拉公司 脱氧胞苷激酶抑制剂的结晶形式及其用途
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
AU2023410324A1 (en) * 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (es) 1992-12-18 1995-08-21 Hoffmann La Roche
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3437685B2 (ja) 1995-09-12 2003-08-18 株式会社東芝 交直変換装置の制御保護システム
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
KR100488038B1 (ko) * 1997-05-23 2005-05-09 프레드라그 시키릭 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
US6426383B1 (en) 1997-05-28 2002-07-30 Nalco Chemical Company Preparation of water soluble polymer dispersions from vinylamide monomers
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
ATE255575T1 (de) 1998-09-29 2003-12-15 Wyeth Corp Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
JP4931313B2 (ja) 2000-01-11 2012-05-16 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド ポリファーマコフォア剤
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EA010184B1 (ru) 2001-04-06 2008-06-30 Уайт Применение противоопухолевых комбинаций рапамицина с гемцитабином или 5-фторурацилом
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
PL367267A1 (en) 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
DE60232370D1 (de) 2001-06-14 2009-06-25 Univ California Mutationen in der mit der resistenz gegenüber sti-
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AR037438A1 (es) 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2003106622A2 (en) 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
DE60310922T2 (de) 2002-06-05 2007-10-11 Cedars-Sinai Medical Center, Los Angeles Gefitinib (iressa) zur behandlung von krebs
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
CN1437942A (zh) 2003-02-08 2003-08-27 杭州华卫制药技术开发有限公司 注射用长春瑞滨粉针剂及制备方法
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DE602004004520T2 (de) 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005018677A2 (en) 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
CN1835923A (zh) 2003-08-19 2006-09-20 惠氏控股公司 制备4－氨基－3－喹啉腈的方法
BR0318503A (pt) 2003-09-15 2006-09-12 Wyeth Corp quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
US7981618B2 (en) 2003-11-05 2011-07-19 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1694330A4 (en) 2003-12-04 2009-06-24 Amr Technology Inc DERIVATIVES OF VINORELBINE
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
AR047988A1 (es) 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
ES2425749T3 (es) 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
US20080286771A1 (en) 2004-07-23 2008-11-20 Kevin Hudson Method of Predicting the Responsiveness of a Tumour to Erbb Receptor Drugs
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
EP1799699A1 (en) 2004-10-13 2007-06-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
US20060084666A1 (en) 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
WO2006085168A2 (en) 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
WO2006081985A1 (en) 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
MX2007009963A (es) 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
EP1854463A4 (en) 2005-03-03 2011-03-23 Takeda Pharmaceutical COMPOSITION WITH CONTROLLED RELEASE
US8105768B2 (en) 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
CA2646257A1 (en) 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
SI1896034T1 (sl) 2005-04-28 2010-07-30 Wyeth Llc Mikronizirani sestavki tanaprogeta in postopki priprave le-tega
AU2006245421A1 (en) 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
CN101203494A (zh) * 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
CA2608394A1 (en) * 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
US20070014859A1 (en) 2005-07-15 2007-01-18 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007039705A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
WO2007050495A2 (en) 2005-10-26 2007-05-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US20070105887A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
PT1948180E (pt) 2005-11-11 2013-05-10 Boehringer Ingelheim Int Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
ATE450266T1 (de) 2005-11-24 2009-12-15 Aicuris Gmbh & Co Kg Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs
JP2007145745A (ja) 2005-11-25 2007-06-14 Osaka Univ 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
WO2007075794A2 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
KR101292508B1 (ko) 2006-04-07 2013-08-01 노파르티스 아게 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
JP2010504974A (ja) 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
EP2073823A1 (en) 2006-10-13 2009-07-01 Medigene AG Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
EP2104501B1 (en) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
EP2121018A2 (en) 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
AR065096A1 (es) 2007-02-01 2009-05-13 Takeda Pharmaceutical Preparacion solida
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP1978106A1 (en) 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
CA2684265A1 (en) 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
EP2205076A4 (en) 2007-09-24 2010-12-29 Tragara Pharmaceuticals Inc POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
US20100298760A1 (en) 2007-11-05 2010-11-25 Bernat Olle Methods, kits, and compositions for administering pharmaceutical compounds
CN101185633A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
JP2011505873A (ja) 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
US20110104256A1 (en) 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
WO2009121031A1 (en) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2725390C (en) 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
WO2010045318A2 (en) 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
JP2012508244A (ja) 2008-11-07 2012-04-05 エンゾン ファーマシューティカルズ，インコーポレーテッド ＥｒｂＢ−３（ＨＥＲ３）選択的併用療法
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
WO2010104406A1 (en) 2009-03-11 2010-09-16 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN102470109A (zh) 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
KR20110007984A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011008054A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011025267A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101190953B1 (ko) 2009-08-25 2012-10-12 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
US20110055838A1 (en) 2009-08-28 2011-03-03 Moyes William A Optimized thread scheduling via hardware performance monitoring
EP2470212A4 (en) 2009-10-01 2013-12-04 Csl Ltd METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
AU2010316683B2 (en) 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
WO2011069962A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
CA2783743C (en) 2009-12-11 2022-10-04 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

Also Published As

Publication number Publication date
CA2928071C (en) 2017-04-25
US20110313166A1 (en) 2011-12-22
NZ616136A (en) 2015-04-24
SG185312A1 (en) 2012-11-29
EP2258698A2 (en) 2010-12-08
CA2702930C (en) 2016-07-05
MX342681B (es) 2016-10-07
ES2586435T3 (es) 2016-10-14
US20120289545A1 (en) 2012-11-15
ES2602123T3 (es) 2017-02-17
KR20180041753A (ko) 2018-04-24
CN106822127A (zh) 2017-06-13
HK1187619A1 (en) 2014-04-11
JP2015127352A (ja) 2015-07-09
JP2023164747A (ja) 2023-11-10
IL308687A (en) 2024-01-01
EP2212311A2 (en) 2010-08-04
JP2021185200A (ja) 2021-12-09
CN117143077A (zh) 2023-12-01
KR20130025862A (ko) 2013-03-12
RU2621719C2 (ru) 2017-06-07
WO2009052264A3 (en) 2009-06-11
CN116715654A (zh) 2023-09-08
JP2013053170A (ja) 2013-03-21
JP2020111606A (ja) 2020-07-27
MX2021013585A (es) 2022-05-18
US20130281488A1 (en) 2013-10-24
US8022216B2 (en) 2011-09-20
CL2008003088A1 (es) 2009-03-20
US20260092046A1 (en) 2026-04-02
IL258440A (en) 2018-05-31
JP2011063610A (ja) 2011-03-31
AR103866A2 (es) 2017-06-07
KR20150039872A (ko) 2015-04-13
EP3088398A1 (en) 2016-11-02
CN101918390B (zh) 2014-06-18
EP2626353A1 (en) 2013-08-14
JP5965640B2 (ja) 2016-08-10
IL205024A0 (en) 2010-11-30
KR101208301B1 (ko) 2012-12-05
JP6412090B2 (ja) 2018-10-24
EP2617719A1 (en) 2013-07-24
EP2537843A2 (en) 2012-12-26
US20090176827A1 (en) 2009-07-09
KR20100069708A (ko) 2010-06-24
JP2018109071A (ja) 2018-07-12
CN110452221A (zh) 2019-11-15
SG10201900175TA (en) 2019-02-27
BRPI0818464B1 (pt) 2020-06-30
HK1146405A1 (en) 2011-06-03
EP2258698A3 (en) 2011-02-16
CA2928071A1 (en) 2009-04-23
NZ705641A (en) 2016-07-29
BR122019023745B1 (pt) 2021-02-02
CA2702930A1 (en) 2009-04-23
RU2010115089A (ru) 2011-11-27
TW200934761A (en) 2009-08-16
BR122019023745B8 (pt) 2021-07-27
US9139558B2 (en) 2015-09-22
MX2010004173A (es) 2010-04-30
US20170320852A1 (en) 2017-11-09
JP2017043640A (ja) 2017-03-02
CN106822127B (zh) 2022-07-29
RU2012126864A (ru) 2014-01-10
CN101918390A (zh) 2010-12-15
EP2537843B1 (en) 2016-09-14
EP2617719B1 (en) 2016-05-11
US20160068511A1 (en) 2016-03-10
KR20160136474A (ko) 2016-11-29
US10035788B2 (en) 2018-07-31
EP2537843A3 (en) 2013-03-13
US8173814B2 (en) 2012-05-08
NZ600349A (en) 2013-12-20
CN103554086A (zh) 2014-02-05
BRPI0818464A2 (pt) 2016-01-05
WO2009052264A2 (en) 2009-04-23
AU2008312474A1 (en) 2009-04-23
MX349332B (es) 2017-07-21
JP2012067131A (ja) 2012-04-05
RU2463300C2 (ru) 2012-10-10
IL205024B (en) 2018-04-30
CN116715653A (zh) 2023-09-08
AU2008312474B2 (en) 2014-01-16
EP2626353B1 (en) 2016-11-23
JP2025137789A (ja) 2025-09-19
JP2011500712A (ja) 2011-01-06
PA8800701A1 (es) 2009-05-15
MX387683B (es) 2025-03-18
BRPI0818464B8 (pt) 2021-05-25
ES2612273T3 (es) 2017-05-16
US9630946B2 (en) 2017-04-25
AR068932A1 (es) 2009-12-16
US8394959B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
IN2015DN01135A (es)
NZ603478A (en) 2 -aminopyridine derivatives useful as inhibitors of atr kinase
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
PL2387563T5 (pl) Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka
NZ590334A (en) ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
MX368173B (es) Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
WO2009068625A3 (en) Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
MX2009013077A (es) Derivados dde benzoxazolona.
IL239170A0 (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist, and compositions containing this substance
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
WO2010016683A3 (ko) 탈모의 예방, 치료, 또는 육모용 조성물
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
MX2008015250A (es) Sales de acido clorhidrico de la 6-metoxi-8-[4-(1-(5-fluoro)-quino lin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina.
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases
MX2009004625A (es) Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas.
WO2006085330A3 (en) Use of protein tyrosine kinase inhibitors for the treatment of leiomyomas
EA201101038A1 (ru) Производные пиридазинона
NZ602758A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
SI2387563T1 (sl) Malatna sol N-(4-((6,7-bis(metiloksi)kinolin-4-il)oksi)fenil-N'-(4-lurofenil)-ciklo- propan-1,1-dikarboksamida in njene kristalinične oblike za zdravljenje raka
NZ620914A (en) Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors